CN116121245B - 小分子rna及其在子宫内膜异位症早期诊断中的应用 - Google Patents
小分子rna及其在子宫内膜异位症早期诊断中的应用 Download PDFInfo
- Publication number
- CN116121245B CN116121245B CN202211009286.0A CN202211009286A CN116121245B CN 116121245 B CN116121245 B CN 116121245B CN 202211009286 A CN202211009286 A CN 202211009286A CN 116121245 B CN116121245 B CN 116121245B
- Authority
- CN
- China
- Prior art keywords
- rna
- endometriosis
- seq
- reagent
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000009273 Endometriosis Diseases 0.000 title claims abstract description 35
- 150000003384 small molecules Chemical class 0.000 title claims description 10
- 238000013399 early diagnosis Methods 0.000 title abstract description 10
- 230000014509 gene expression Effects 0.000 claims abstract description 30
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 23
- 238000003745 diagnosis Methods 0.000 claims abstract description 15
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 38
- 238000001514 detection method Methods 0.000 claims description 21
- 210000002700 urine Anatomy 0.000 claims description 20
- 210000002966 serum Anatomy 0.000 claims description 17
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 8
- 238000010839 reverse transcription Methods 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 239000003161 ribonuclease inhibitor Substances 0.000 claims description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 2
- 238000012408 PCR amplification Methods 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 19
- 102000039446 nucleic acids Human genes 0.000 abstract description 9
- 108020004707 nucleic acids Proteins 0.000 abstract description 9
- 230000008901 benefit Effects 0.000 abstract description 6
- 238000003759 clinical diagnosis Methods 0.000 abstract description 2
- 239000002547 new drug Substances 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 25
- 238000000034 method Methods 0.000 description 9
- 210000004696 endometrium Anatomy 0.000 description 8
- 238000003753 real-time PCR Methods 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000011065 in-situ storage Methods 0.000 description 7
- 210000002304 esc Anatomy 0.000 description 5
- 108091027963 non-coding RNA Proteins 0.000 description 5
- 102000042567 non-coding RNA Human genes 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000012165 high-throughput sequencing Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 208000016216 Choristoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011528 liquid biopsy Methods 0.000 description 2
- 239000003147 molecular marker Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
子宫内膜异位症(n=5) | 对照组(n=5) | ||
年龄 | 34.5±5.5 | 32.5±8.5 | p>0.05 |
BMI | 23.4±1.2 | 23.1±4.1 | p>0.05 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211009286.0A CN116121245B (zh) | 2022-08-22 | 2022-08-22 | 小分子rna及其在子宫内膜异位症早期诊断中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211009286.0A CN116121245B (zh) | 2022-08-22 | 2022-08-22 | 小分子rna及其在子宫内膜异位症早期诊断中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116121245A CN116121245A (zh) | 2023-05-16 |
CN116121245B true CN116121245B (zh) | 2023-08-01 |
Family
ID=86310605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211009286.0A Active CN116121245B (zh) | 2022-08-22 | 2022-08-22 | 小分子rna及其在子宫内膜异位症早期诊断中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116121245B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108676874A (zh) * | 2018-08-27 | 2018-10-19 | 复旦大学附属妇产科医院 | 循环外泌体长链非编码rna-tc0101441作为诊断子宫内膜异位症的标记物用途 |
CN109593845A (zh) * | 2019-01-25 | 2019-04-09 | 河北仁博科技有限公司 | miRNA作为诊断子宫内膜异位症的标记物的用途 |
CN114350812A (zh) * | 2022-01-25 | 2022-04-15 | 江苏省人民医院(南京医科大学第一附属医院) | 与奥西替尼耐药性相关的NSCLC-free RNA-3及其应用 |
CN114703272A (zh) * | 2022-02-11 | 2022-07-05 | 南京市妇幼保健院 | 一种妊娠糖尿病性巨大儿高危孕妇筛查或早期诊断试剂盒 |
-
2022
- 2022-08-22 CN CN202211009286.0A patent/CN116121245B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108676874A (zh) * | 2018-08-27 | 2018-10-19 | 复旦大学附属妇产科医院 | 循环外泌体长链非编码rna-tc0101441作为诊断子宫内膜异位症的标记物用途 |
CN109593845A (zh) * | 2019-01-25 | 2019-04-09 | 河北仁博科技有限公司 | miRNA作为诊断子宫内膜异位症的标记物的用途 |
CN114350812A (zh) * | 2022-01-25 | 2022-04-15 | 江苏省人民医院(南京医科大学第一附属医院) | 与奥西替尼耐药性相关的NSCLC-free RNA-3及其应用 |
CN114703272A (zh) * | 2022-02-11 | 2022-07-05 | 南京市妇幼保健院 | 一种妊娠糖尿病性巨大儿高危孕妇筛查或早期诊断试剂盒 |
Non-Patent Citations (3)
Title |
---|
Analysis of Serum microRNA Profile by Solexa Sequencing in Women With Endometriosis;Lei Wang et al.;《Reproductive Sciences》;1359-1370 * |
miR-363 靶基因预测及生物信息学分析;李文衢 等;《南京医科大学学报(自然科学版)》;911-917 * |
微小RNA 在子宫内膜异位症中的研究进展;洪雅艺 等;《国际妇产科学杂志》;277-231 * |
Also Published As
Publication number | Publication date |
---|---|
CN116121245A (zh) | 2023-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2691404T3 (es) | Diagnóstico no invasivo del cáncer | |
CN109055563B (zh) | 结直肠癌相关环状rna基因、结直肠癌分子标志物及其应用 | |
CN109609630B (zh) | 用于早期胃癌诊断的分子标志物及其应用 | |
CN109055555B (zh) | 一种肺癌早期转移诊断标志物及其试剂盒和应用 | |
CN109161593B (zh) | 环状RNA和microRNA在结直肠癌筛查诊断的应用 | |
CN110229899B (zh) | 用于结直肠癌早期诊断或预后预测的血浆标记物组合 | |
CN113999909B (zh) | 一种用于胃癌诊断的血清外泌体标志物及其应用、扩增引物对和诊断试剂盒 | |
CN114717305A (zh) | Nr1d1、junb、rorc作为药物性-急性肾损伤的诊断标记应用 | |
CN111424085B (zh) | tRNA来源片段在制备乳腺癌诊断试剂中的应用 | |
CN109022583A (zh) | hsa_circ_0021977在制备诊断乳腺癌产品上的应用 | |
CN109536502B (zh) | 一种适用于妊娠滋养细胞肿瘤患者血浆外泌体miRNA的PCR内参 | |
CN116121245B (zh) | 小分子rna及其在子宫内膜异位症早期诊断中的应用 | |
CN110257514A (zh) | 一种新的食管癌血液miRNA标志物及其应用 | |
CN106755330B (zh) | 癌症相关基因表达差异检测试剂盒及其应用 | |
CN112646876B (zh) | 用于银屑病诊断的miRNA及其应用 | |
CN112522391B (zh) | hsa_circ_0008961作为痛风诊断标志物的应用 | |
KR102505618B1 (ko) | 신장이식 후 항체 매개성 거부반응의 진단을 위한 소변 엑소좀 유래 miRNA 유전자 바이오마커 및 이의 용도 | |
WO2021159562A1 (zh) | 一种与泛肿瘤辅助诊断相关的循环miRNA和癌胚miRNA标志物及其应用 | |
CN114350812A (zh) | 与奥西替尼耐药性相关的NSCLC-free RNA-3及其应用 | |
CN109988834A (zh) | 血浆外泌体分子标志物has-miR-219a-5p及应用 | |
CN109762897B (zh) | 一种骨肉瘤生物标记物环状RNA-circ_0006633及其应用 | |
CN116162705B (zh) | 一种胃癌诊断产品和诊断模型 | |
CN114752676B (zh) | 检测hsa_circ_0099132的试剂在制备人结直肠癌辅助诊断试剂盒中的应用 | |
CN115820858B (zh) | 一种血清在制备云南宣威肺癌诊断药物中的应用 | |
CN112176060B (zh) | 一组血浆非编码rna及检测其表达水平的引物组与结直肠癌检测试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240412 Address after: 210000, Room 101, Building 9, Qinhefang, Chunjiang New City, Yuhuatai District, Nanjing City, Jiangsu Province Patentee after: Nanjing Beima Biotechnology Co.,Ltd. Country or region after: China Address before: No.123, Tianfei lane, Mochou Road, Nanjing, Jiangsu 210004 Patentee before: NANJING MATERNITY AND CHILD HEALTH Hospital Country or region before: China |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240425 Address after: Floor E6-9, Jiangsu Life Science and Technology Innovation Park, No. 9 Weidi Road, Xianlin Street, Qixia District, Nanjing City, Jiangsu Province, 210000 Patentee after: Nanjing Meili Pharmaceutical Technology Co.,Ltd. Country or region after: China Address before: 210000, Room 101, Building 9, Qinhefang, Chunjiang New City, Yuhuatai District, Nanjing City, Jiangsu Province Patentee before: Nanjing Beima Biotechnology Co.,Ltd. Country or region before: China |
|
TR01 | Transfer of patent right |